Business Wire

Aqara To Unveil New Smart Home Devices at IFA 2023, Embracing the Future of Connected Living

31.8.2023 10:00:00 EEST | Business Wire | Press release

Share

Aqara, a leading provider of smart home products, is thrilled to announce its attendance at this year’s IFA show, where it will unveil multiple new smart home devices. These include the Smart Lock U200, the Camera E1, the Dual Relay Module T2, the Ceiling Light T1M, and an EU-style wall outlet. Aqara will be showcasing these new devices along with other smart home technology and solutions at its booth (H22, 214).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831580646/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Aqara unveils new smart home devices at IFA 2023 (Photo: Business Wire)

With a commitment to making smart home technology more accessible to households worldwide, Aqara continues to expand its product portfolio to enable various home automation use cases. The five new products previewed at IFA are expected to become available for order in the coming months.

Smart Lock U200 - As a retrofit solution, Aqara’s new Smart Lock U200 offers the convenience of keyless home access to a broad user base. The lock operates with existing cylinders and requires no drilling or door modifications. As Aqara’s first Matter-over-Thread smart lock, the U200 will be interoperable with a wide array of smart home ecosystems and products. Using an Aqara NFC card or specified NFC-enabled mobile devices, users can unlock easier than ever before. Other secure access options include auto-unlock, fingerprints, PIN codes and mobile apps. Aqara also plans to initiate its first crowdfunding campaign on Kickstarter for the Smart Lock U200 later this year.

Camera E1 - Aqara is expanding its home surveillance camera portfolio with the 2K, Pan/Tilt Camera E1. Similar to other indoor home cameras from the Company, this new camera supports major third-party platforms like Apple Home (including HomeKit Secure Video), Amazon Alexa, and Google Home. Built upon Wi-Fi 6 and Bluetooth 5.2, the camera enables smoother live view and easier pairing experience. Other features of the E1 camera include AI-enabled person detection, person tracking and flexible storage options such as cloud storage, microSD card, and NAS storage.

Dual Relay Module T2 - The Dual Relay Module T2 is a versatile solution for home automation, allowing easy control of various devices ranging from lights, motorized window coverings, garage doors, boilers, to electric heaters and underfloor heating. Built upon Zigbee 3.0, the dual relay module features Matter-over-bridge support and is compatible with major third-party platforms. It also allows users to monitor energy consumption and ensures peace of mind with safety features like overheat protection, overload protection, and configurable power limits. Powered by AC (100-250V) or DC (24-60V), the 2-channel relay supports a total (and per-channel) loads of up to 10 Amps.

Ceiling Light T1M - Following the LED Strip T1, which was announced in August 2023, Aqara is introducing its second smart lighting device to the global market. With an approximate diameter of 50 centimeters, the Ceiling Light T1M offers a broad spectrum of hues from dimmable whites to 16 million vibrant colors, allowing users to set the atmospheric lighting for different occasions and moods. Additional features include an independently addressable RGB ring for gradient effects and integration into home automation, such as using the RGB ring as a status light to indicate potential threats like an open door or water leak. Similar to other Zigbee devices from Aqara, the Ceiling Light T1M features the low idle consumption, Matter-over-bridge support, and the wide compatibility with major platforms.

EU-style wall outlet - Finally, Aqara is introducing a smart wall socket for the EU market. This outlet allows easy control of plugged devices via mobile apps, voice assistants and home automation. It also helps users track energy consumption. Moreover, this new outlet can be configured to sense and report the status of the plugged device, making it possible to use the on/off status of an appliance as an automation trigger. For example, to close the curtains and dim the lights when the TV is turned on, or to notify the user when the washing machine finished the laundry. As a repeater of the Zigbee network, this socket outlet also enhances network reliability and responsiveness of other compatible smart home devices.

“Aqara is at the forefront of innovating the smart home experience, and these new products are a testament to our dedication. Each of them is crafted with the user's convenience and lifestyle in mind, reflecting our commitment to quality and innovation,” said Cathy You, Aqara Senior Vice President, Global Business and Strategy. “We invite everyone to join us at our booth to experience firsthand the future we're building together.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Inquiries:
media@aqara.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye